Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.37 and traded as high as $1.70. Cortexyme shares last traded at $1.67, with a volume of 274,744 shares changing hands.
Cortexyme Trading Down 3.0%
The business's fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $1.37. The stock has a market capitalization of $48.24 million, a P/E ratio of -0.54 and a beta of 1.40.
About Cortexyme
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
